Meta-analyses depend upon having trials with large numbers of patients. In this meta-analysis, however, a number of the trials had low numbers of patients -between 20 and 40 in each group.
Introduction
The study by Messori et al attempts, by way of performing meta-analyses, to assess or determine the effectiveness of ranitidine sucralfate in the prevention of stress ulceration. It also performs further metaanalysis to assess these treatments and their risk of nosocomial pneumonia.
Ranitidine and sucralfate are widely used to prevent stress ulceration.Ranitidine is a histamine-2 receptor antagonist and acts by regulation of HCl production at the parietal cells in the stomach. Sucralfate is an aluminium hydroxide sulphated sucrose complex which coats the gastric surface, anion binding to positively charged proteins. This may prevent diffusion of hydrodgen ions an also stimulates mucus and bicarbonate production and prostaglandin secretion.
The paper aims to provide five separate meta-analyses:
• A-ranitidine versus placebo -rate of bleeding
• B-sucralfate versus placebo -rate of bleeding
• C-ranitidine versus placebo -incidence of nosocomial pneumonia
• D-sucralfate versus placebo -incidence of nosocomial pneumonia
• E-ranitidine versus sucralfate -incidence of nosocomial pneumonia
Methods
• The meta-analysis search for randomised trials was performed by keyword searching (keywords: stress, pneumonia, ranitidine, sucralfate, randomised controlled trial/random) the following medical literature databases; Medline 1966-2000, Iowa-IDIS system, Drugdex
• Each trial is assessed using a scoring system based on the testing of variables (termed the 'Methodological Quality'). Each appropriate randomised study is rated and given a score based on the following selection criteria; patient selection, patient characteristics, randomisation, blinding, definition of pneumonia and or bleeding.
• Data synthesis -Odds ratios based on the random effect model
Results
Rate of bleeding:
• A-ranitidine versus placebo; five trials, 398 pts: SD (mean quality score) 6.6; no significant benefit odds ratio 0.95, 0.37 to 2.43, P = 0.92
• B-sucralfate versus placebo; one trial, 54 pts; SD; odds ratio 1.26, 0.12 to 12.9, P = 0.7
Incidence of nosocomial pneumonia:
• C-ranitidine versus placebo; three trials, 311 pts; SD 6; no significant difference; odds ratio 1.10, 0.45 to 2.66, P = 0.84
• D-sucralfate versus placebo; two trials, 226 pt; SD 6; odds ratio 2.11, 0.79 to 5.64, P = 0.14 • E-ranitidine versus sucralfate; eight trials, 1825 pts; SD 5.6; odds ratio 1.51,1.0 to 2.29, P = 0.05
